



Express Mail No. EV449563042US
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Tomas R. Szabo et al.
Application No. : 10/020,867
Filed : December 14, 2001
For : COBALT-PORPHYRIN COMPLEXES AND USE THEREOF AS
AN ANTI-OBESITY AGENT

Examiner : Peter G. O'Sullivan
Art Unit : 1621
Docket No. : 660088.415
Date : November 8, 2004

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT

Commissioner for Patents:

In response to the Office Action mailed May 6, 2004, please extend the period of time for response three months, to expire on November 8, 2004 (November 6, 2004 being a Saturday and November 7, 2004 being a Sunday). Enclosed are a Petition for an Extension of Time and the requisite fee. Please amend the application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.


Remarks/Arguments begin on page 5 of this paper.

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A cobalt-porphyrin complex having the structure:



or a salt thereof, wherein:

R₁ and R₂ are both -(CH₂)₂C(=O)OCH(CH₃)₂; the same or different and independently (CH₂)_n-A-R₅, wherein A is C(=O)O, OC(=O), C(=O)N(R), N(R)C(=O), -C(=O), N(R), O or S, and R is hydrogen, alkyl, substituted alkyl, arylalkyl, or substituted arylalkyl, and n is 2 or 3;

R₃ and R₄ are both the same or different and independently CH=CH₂ or -CH₂CH₃; and

R₅ is, at each occurrence, the same or different and independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl or substituted arylalkyl; and


L₁ and L₂ are both glycinate optional ligands;

and with the proviso that the cobalt-porphyrin complex of structure (I) has no more than 5% of the redox activity of cobalt mesoporphyrin.

2-30. (Cancelled)

31. (Original) A composition comprising a compound of claim 1 in combination with a pharmaceutically acceptable carrier.

32. (Currently Amended) A method for treating obesity, comprising administering an effective amount of a composition comprising a cobalt-porphyrin complex and a pharmaceutically acceptable carrier, wherein the cobalt-porphyrin complex has the structure:



or a salt thereof, wherein:

R₁ and R₂ are both -(CH₂)₂C(=O)OCH(CH₃)₂; the same or different and independently (CH₂)_n-A-R₅, wherein A is C(=O)O, OC(=O), C(=O)N(R), N(R)C(=O), C(=O), O or S, and R is hydrogen, alkyl, substituted alkyl, arylalkyl, or substituted arylalkyl, and n is 2 or 3;

R₃ and R₄ are both the same or different and independently CH=CH₂ or -CH₂CH₃; and

R₅ is, at each occurrence, the same or different and independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl or substituted arylalkyl; and

L₁ and L₂ are both glycinate optional ligands;

and with the proviso that the cobalt-porphyrin complex of structure (I) has no more than 50% of the redox activity of cobalt mesoporphyrin.

Application No. 10/020,867
Reply to Office Action mailed May 6, 2004

33-62. (Cancelled)